Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Left Ventricular Ejection Fraction (LVEF)
NCT ID: NCT01481402
Last Updated: 2019-07-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
21 participants
INTERVENTIONAL
2011-07-31
2014-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Developing Oral LT3 Therapy for Heart Failure - HFrEF
NCT04112316
Developing Oral LT3 Therapy for Heart Failure - HFpEF
NCT04111536
Effects of Triiodothyronine (T3) in Ischemic Heart Failure
NCT05384847
Study of DITPA in Patients With Congestive Heart Failure
NCT00103519
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo-liothyronine
3 months of placebo followed by 3 months of Liothyronine treatment.
Liothyronine
Liothyronine 40 microgram per day
Liothyronine-Placebo
3 months of Liothyronine treatment followed by 3 months of Placebo treatment.
Liothyronine
3 months of placebo followed by 3 months of Liothyronine 40 microgram per day (oral)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Liothyronine
Liothyronine 40 microgram per day
Liothyronine
3 months of placebo followed by 3 months of Liothyronine 40 microgram per day (oral)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* T3 ≤1.4 nmol/l in two blood samples, TSH is to be normal
* LVEF ≤ 45 % on prior echocardiography
Exclusion Criteria
* Atrial fibrillation/flutter
* More than 20% ventricular extrasystoles
* Severe chronic obstructive lung disorder
* Pregnancy. Pregnancy testing will be done for fertile women
* Age \< 18 years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jens Faber
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jens Faber
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jens Faber, MDSci
Role: STUDY_DIRECTOR
Herlev Hospital, Dept. of Endocrinology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Herlev Hospital, Dept. of Endocrinology
Herlev, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HerlevH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.